Athira Pharma, Inc. (ATHA)
NASDAQ: ATHA · Real-Time Price · USD
0.434
-0.014 (-3.21%)
Feb 21, 2025, 4:00 PM EST - Market closed
Athira Pharma Employees
As of December 31, 2023, Athira Pharma had 67 total employees, including 65 full-time and 2 part-time employees. The number of employees increased by 3 or 4.69% compared to the previous year.
Employees
67
Change (1Y)
3
Growth (1Y)
4.69%
Revenue / Employee
n/a
Profits / Employee
-$1,630,179
Market Cap
16.79M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 67 | 3 | 4.69% |
Dec 31, 2022 | 64 | 29 | 82.86% |
Dec 31, 2021 | 35 | 13 | 59.09% |
Dec 31, 2020 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ATHA News
- 6 weeks ago - Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - GeekWire
- 2 months ago - Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND - GlobeNewsWire
- 3 months ago - Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates - GlobeNewsWire
- 5 months ago - Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring - GeekWire
- 5 months ago - Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - GlobeNewsWire
- 6 months ago - Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks - Benzinga
- 6 months ago - Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial - Reuters
- 6 months ago - Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease - GlobeNewsWire